Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07133074 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Allergy Delabeling in Antibiotic Stewardship - Intervention

Study acronym: RENEW-IN
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase changed: not applicable → Phase 4 Sponsor changed: Ebbing Lautenbach to Abramson Cancer Center at Penn Medicinev5 Show 1 more changeShow less
    • Sponsor changed: Ebbing Lautenbach to Abramson Cancer Center at Penn Medicine

    See this version in full on ClinicalTrials.gov ↗

  2. Recruitment opened Study sites: 0 to 1 · Start date changed from estimate of May 2026 to Apr 20, 2026v4 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2026 to Apr 20, 2026
  3. Start date: Feb 2026 to May 2026v3
  4. Start date: Nov 2025 to Feb 2026v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
Trial Details
NCT Number NCT07133074
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: University of Utah
Conditions Beta Lactam Allergy, Hematologic Malignancy
Enrollment 3,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov